Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Benda Not Able to Capitalize on Gene Therapy Cancer Drug

publication date: Aug 15, 2008

Benda Pharmaceutical, Inc., which produces the gene-therapy cancer drug Gendicine® along with TCM products and conventional pharmaceuticals, reported that Q2 revenues climbed 40% to $7.3 million. Nevertheless, the company still suffered a loss of $1.8 million in the quarter, though that loss was a significant improvement over the $8.8 million that Benda lost in the year-earlier quarter. The results from the company’s SiBiono subsidiary, which produces Gendicine, were not as positive. Revenues dropped 47% in the period to $800,000. More details...

Stock Symbol: (OTCBB: BPMA)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital